Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AGS-499
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Israel Innovation Authority
Deal Size : $0.5 million
Deal Type : Funding
Details : The IIA funds will be used towards advancing AGS-499, Neuromagen's lead drug candidate to IND submission and to first-in-human clinical trials which are expected during 2024.
Product Name : AGS-499
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 22, 2022
Lead Product(s) : AGS-499
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Israel Innovation Authority
Deal Size : $0.5 million
Deal Type : Funding
Reset All
